Photo: Camila Mofsovich / Unsplash
In the MAJESTY trial, 36% of adults on obinutuzumab reached complete remission of proteinuria at two years, versus 6% on tacrolimus.
Background
Primary membranous nephropathy (PMN) is a rare kidney disease in which the immune system attacks the glomeruli, the kidney's filtering units, causing large amounts of protein to leak into the urine [1]. Complications include high cholesterol, high blood pressure, severe swelling, fatigue and kidney failure [1]. Roche, Genentech's parent company, puts US incidence at about 1.2 cases per 100,000 people per year and says up to 30% of untreated patients progress to kidney failure within 10 years [2].
Until now, no drug had been approved specifically for the condition. Clinicians have relied on immunosuppressants used off-label, including tacrolimus [1].
What Happened
On November 13, 2026, the FDA approved Gazyva (obinutuzumab) for adults with PMN who are at risk of disease progression, to induce remission of proteinuria [1]. The agency called it "the first drug approved specifically" for adults with the disease [1]. Gazyva, an antibody that targets the CD20 protein on B cells and is given by intravenous infusion [3], was already approved for certain cancers, active lupus nephritis and childhood-onset idiopathic nephrotic syndrome [1].
The application carried Breakthrough Therapy, Orphan Drug and Priority Review designations [1]. Roche announced the approval on November 16 and noted that PMN is Gazyva's third FDA-approved indication in immune-mediated kidney disease [2].
Marc Hurlbert, chief executive of the National Kidney Foundation, called the approval "a milestone" in a statement included in Roche's release [2]. For a disease whose standard of care has been borrowed from other indications, a label of its own is not a small thing.
Study Design and Limitations
The approval rests on MAJESTY (NCT04629248), a Phase 3, randomized, open-label, multicenter trial that enrolled 142 adults with PMN and compared Gazyva with tacrolimus [1]. The primary endpoint was complete remission of proteinuria at week 104, defined as a urine protein-to-creatinine ratio of 0.3 g/g or less with stable kidney function (eGFR) [1]. Patients who needed rescue therapy, had treatment failure or stopped treatment early were counted as not achieving remission [1].
At week 104, 36% of patients on Gazyva achieved complete remission, compared with 6% on tacrolimus, a statistically significant difference [1]. Roche reported the more precise figures as 36.1% versus 5.7% (adjusted difference 31.1 percentage points; 95% CI, 18.2 to 44.0) [2]. According to Roche, complete or partial remission at week 104 occurred in 50% versus 12.9% of patients, and complete remission at week 76 in 36.1% versus 8.6% [2]. The secondary figures come from the company, not the FDA announcement.
Several caveats apply. The trial was open-label, so patients and investigators knew who received which drug [1]. Its endpoint is a laboratory marker, proteinuria remission, rather than kidney failure itself; Rare Daily reported that Genentech did not say whether Gazyva reduced kidney failure rates [3]. And at 142 patients, the trial is modest in size, as is typical for rare diseases [1].
Gazyva carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection that occurs in people with weakened immune systems [1]. The most common side effects in the PMN study were infusion-related reactions and upper respiratory tract infections [1]. Rare Daily, citing the company, reported that serious infections occurred more often than with tacrolimus [3]. Roche said no new safety signals were identified [2].
What Comes Next
Roche said the PMN data are being submitted to other health authorities, including the European Medicines Agency [2]. Separately, Gazyva is under FDA review for systemic lupus erythematosus, with a decision expected by December 2026, according to the company [2]. MAJESTY results were presented at the ERA Congress in June 2026 and published in the New England Journal of Medicine, Roche said [2]. Longer follow-up on hard kidney outcomes will determine how much the remission advantage translates into patients staying off dialysis. Readers can find full safety details in the prescribing information.
This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.
References
U.S. Food and Drug Administration. FDA approves first drug to treat adults with primary membranous nephropathy. FDA. November 13, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy
Roche. Roche's Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy. Roche media release. November 16, 2026. https://www.roche.com/media/releases/med-cor-2026-11-16
Rare Daily. FDA approves first treatment for rare autoimmune kidney disease. Global Genes. November 16, 2026. https://globalgenes.org/raredaily/fda-approves-first-treatment-for-rare-autoimmune-kidney-disease/